Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia / 医学前沿
Frontiers of Medicine
;
(4): 718-727, 2021.
Article
in English
| WPRIM
| ID: wpr-922504
ABSTRACT
Severe aplastic anemia II (SAA-II) progresses from non-severe aplastic anemia (NSAA). The unavailability of efficacious treatment has prompted the need for haploidentical bone marrow transplantation (haplo-BMT) in patients lacking a human leukocyte antigen (HLA)-matched donor. This study aimed to investigate the efficacy of haplo-BMT for patients with SAA-II. Twenty-two patients were included and followed up, and FLU/BU/CY/ATG was used as conditioning regimen. Among these patients, 21 were successfully engrafted, 19 of whom survived after haplo-BMT. Four patients experienced grade II-IV aGvHD, including two with grade III-IV aGvHD. Six patients experienced chronic GvHD, among whom four were mild and two were moderate. Twelve patients experienced infections during BMT. One was diagnosed with post-transplant lymphoproliferative disorder and one with probable EBV disease, and both recovered after rituximab infusion. Haplo-BMT achieved 3-year overall survival and disease-free survival rate of 86.4% ± 0.73% after a median follow-up of 42 months, indicating its effectiveness as a salvage therapy. These promising outcomes may support haplo-BMT as an alternative treatment strategy for patients with SAA-II lacking HLA-matched donors.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Bone Marrow Transplantation
/
Hematopoietic Stem Cell Transplantation
/
Transplantation Conditioning
/
Graft vs Host Disease
/
HLA Antigens
/
Anemia, Aplastic
Limits:
Humans
Language:
English
Journal:
Frontiers of Medicine
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS